It has been reported in several studies that ionized hypomagnesemia is associated with higher morbidity and mortality rates. During continuous renal replacement therapy with regional citrate anticoagulation (CRRT-RCA), the loss of magnesium has been reported to not be covered by magnesium concentration in ordinary dialysis fluid. This may lead to ionized hypomagnesemia. However the incidence of ionized hypomagnesemia in patients requiring CRRT-RCA remains unclear and need to be estimated to determine if ionized magnesium monitoring could be of interest. This study aim to assess the incidence of ionized hypomagnesemia induced by CRRT-RCA.

开始日期2020-05-01

申办/合作机构

Centre Hospitalier Universitaire de Montpellier

[+1]

100 项与 NovaMedica LLC 相关的临床结果

登录后查看更多信息

0 项与 NovaMedica LLC 相关的专利（医药）

登录后查看更多信息

项与 NovaMedica LLC 相关的文献（医药）

2023-01-01·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

[Comparative clinical study of pharmacokinetics and bioequivalence of Relonova and Maxalt].

Article

作者: Leykin, Z N ; Khokhlov, A L

OBJECTIVEEvaluation of the bioequivalence of the tested Relonova, tablets, 10 mg and Maxalt, tablets, 10 mg drugs on an empty stomach in healthy volunteers.MATERIAL AND METHODSThe pharmacokinetic analysis population included 40 volunteers, the safety analysis population included 40 volunteers. The average age of randomized volunteers (men - 20, women - 20) was 29.3±8.9 years, height 1.71±0.09 m, body weight 70.86±11.66 kg, mean BMI 24.18±2.81 kg/m². The method used high performance liquid chromatography with tandem mass spectrometric detection. Statistical analysis of the obtained data was performed based on the assumption of a log-normal distribution of the parameters AUC0-72 and Cmax.RESULTSThe ratio of geometric means for the key pharmacokinetic parameters (AUC0-t, AUC0-inf and Cmax) of rizatriptan is close to 90%, CI is within the acceptable range for bioequivalent drugs (80-125%). The intrasubject variability (CVintra) for rizatriptan was 23.74% (Cmax), 10.94% (AUC0-t). The average profiles of the pharmacokinetic curves of rizatriptan when taking the test and reference drugs have similar shapes. Relonova and reference Maxalt are bioequivalent.CONCLUSIONThe results of the study make it possible to recommend Relonova for further clinical study and wide practical application.

Social Psychology and Society

Effect of Managers Competencies on Employee Engagement

作者: Bazarov, T.Y. ; Karpov, A.B.

Objective. Analysis of the connection between the level of development of managerial competencies of a manager and the involvement in the work of both himself and his subordinates. Background. Most managers of modern organizations pay considerable attention to managing employee engagement when working with personnel. One of the key factors influencing employee engagement is the immediate supervisor. It is important to determine the manager’s competencies, through the development of which it is possible to increase the involvement of employees at different levels in the organization. Study design. The work examined the relationship between the involvement of employees at different levels in the organization and the level of development of the competencies of their managers; and differences between executive and employee engagement. The presence and degree of relationships were determined using correlation analysis, and differences were determined by assessing the reliability of differences in mean values. Participants. Employees of the organization: 768 people (24,2% men, 75,8% women): 146 (19%) managers and 622 (81%) employees. Measurements. Methodology for assessing the competencies of managers “360 degrees” based on a corporate model of 8 management competencies; Anonymous engagement questionnaire Kicentric – Russian version. Results. The manager’s competencies “Understanding the Business”, “Result Orientation”, “Interaction” and “Development of Subordinates” contribute to the involvement of subordinates. “Leadership”, “Initiative”, “Business Understanding”, “Interaction” are also interconnected with the leader’s own involvement. “Planning” is an inverse relationship. It has been established that there are differences in the involvement of managers and employees. Сonclusions. There is a relationship between the involvement of employees and the manager with the level of development of his competencies: some competencies of managers are associated with high involvement of him and his employees, some with low. A connection was found between the levels of involvement of the manager and employees. Differences in some parameters of engagement between managers and employees were revealed.

项与 NovaMedica LLC 相关的新闻（医药）

2023-05-10

·PRNewswire

Global Antibiotics Partnering Terms and Agreements 2010 to 2023: Featuring Trends, Disclosed Figures, Contract Documents and Top Deals by Value

DUBLIN, May 10, 2023 /PRNewswire/ -- The "Global Antibiotics Partnering Terms and Agreements 2010 to 2023" report has been added to ResearchAndMarkets.com's offering. The Global Antibiotics Partnering Terms and Agreements 2010 to 2023 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering: Antibiotics Aminoglycosides Cephalosporin Clindamycin Macrolides Penicillin Quinolones Sulfonamides Tetracycline Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains over 340 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products. Report scope Global Antibiotics Partnering Terms and Agreements 2010 to 2023 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide. Global Antibiotics Partnering Terms and Agreements 2010 to 2023 includes: Trends in antibiotics dealmaking in the biopharma industry since 2010 Analysis of antibiotics deal structure Access to headline, upfront, milestone and royalty data Access to over 340 antibiotics deal records and contract documents where available The leading antibody deals by value since 2010 Most active antibiotics dealmakers since 2010 The leading antibiotics partnering resources In Global Antibiotics Partnering Terms and Agreements 2010 to 2023, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Companies Mentioned Oxford Drug Design Gilead Sciences MD Anderson Cancer Center Biomedical Advanced Research and Development Authority Lysando Warp Drive Bio Centre for Drug Research and Development (CDRD) InSite Vision France's General Directorate for Armaments Q-linea AB Basilea Pharmaceutica European Commission European Union XBiotech QureTech Bio AnnaMed Dr. Reddy's Laboratories NovaMedica The Medicines Company The Regents of the University of California Paratek Pharmaceuticals Stiefel Laboratories Decibel Therapeutics NacuGen Therapeutics Quotient Bioresearch Emergent BioSolutions Novasep Polypeptide Laboratory Premier Inc Optimer Pharmaceuticals Auspherix Strides Arcolab Synthetic Biologics Medimetriks SINTEF Dana-Farber Cancer Institute Finorga Allergan For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 项与 NovaMedica LLC 相关的药物交易

登录后查看更多信息

100 项与 NovaMedica LLC 相关的转化医学

登录后查看更多信息